证券代码：301188 证券简称：力诺特玻 公告编号：2023-042 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东力诺特种玻璃股份有限公司（以下简称"公司"）第三届监事会第十七次 会议于 2023 年 8 月 10 日以书面通知形式发出通知，2023 年 8 月 16 日以现场与 通讯相结合的方式在公司 1 号会议室召开。会议由监事会主席张常善先生召集并 主持，本次会议应出席监事 3 名，实际出席监事 3 名，其中以通讯表决方式出席 会议的监事 2 名，分别是张常善、马一。本次会议的召开符合《中华人民共和国 公司法》等法律、法规、规范性文件和《公司章程》的有关规定，会议合法、有 效。 三、备查文件 山东力诺特种玻璃股份有限公司 第三届监事会第十七次会议决议公告 二、监事会会议审议情况 1、审议通过了《关于购买电站资产组暨关联交易的议案》 监事会意见：经核查，监事会认为：公司本次购买济南瑞新新能源有限公 司、济南瑞金新能源有限公司电站资产组暨关联交易事项，是在综合考量公司 实际经营需要基础上做出的决定，符合公司战略发展目标，有利 ...

证券代码：301188 证券简称：力诺特玻 公告编号：2023-041 山东力诺特种玻璃股份有限公司 第三届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 公司独立董事对本议案发表了同意的事前认可意见及独立意见。 公司保荐机构出具了专项核查意见。 2、审议通过了《关于投资设立全资子公司的议案》 1 基于公司战略规划，结合经营发展的需要，公司拟投资设立山东力诺国际贸 易有限公司（暂定名，最终以工商行政管理部门核准登记注册为准），持股比例 为 100%。 详情请参见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《关于投资 设立全资子公司的公告》（公告编号：2023-044）。 山东力诺特种玻璃股份有限公司（以下简称"公司"）第三届董事会第十八 次会议通知于 2023 年 8 月 10 日通过书面通知的方式向全体董事发出。会议于 2023 年 8 月 16 日以现场与通讯相结合的方式在公司 1 号会议室召开,会议由董 事长孙庆法先生召集并主持，本次会议应出席董事 9 名，实际出席董事 9 名，其 ...

现将有关情况公告如下： 二、投资标的基本情况 1、名称：山东力诺国际贸易有限公司 证券代码：301188 证券简称：力诺特玻 公告编号：2023-044 山东力诺特种玻璃股份有限公司 关于投资设立全资子公司的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 山东力诺特种玻璃股份有限公司（以下简称"公司"）于2023年8月16日召 开了第三届董事会第十八次会议，审议通过了《关于投资设立全资子公司的议案》， 同意公司以自有资金投资设立山东力诺国际贸易有限公司（暂定名，最终以工商 行政管理部门核准登记注册为准），拟注册资本为300万元人民币。同时，授权 公司管理层依据法律、法规的规定办理目标公司的工商注册登记等相关工作。 本次对外投资不构成关联交易，不构成重大资产重组，根据《公司章程》等 有关规定，该事项属于公司董事会审批权限，无需提交公司股东大会。 三、本次对外投资目的、对公司的影响及存在的风险 本次对外投资子公司的资金来源为自有资金，不会对公司的经营及财务状况 产生不利影响，也不存在损害公司及全体股东权益的情形。投资标的设立后存在 一定的经 ...

民生证券股份有限公司 关于山东力诺特种玻璃股份有限公司 购买电站资产组暨关联交易的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为山东 力诺特种玻璃股份有限公司（以下简称"力诺特玻"或"公司"）首次公开发行 股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关规定，对力诺特玻购买电站资产组暨关联交易事项进 行了核查，具体情况如下： 一、关联交易概况 基于公司长期战略规划所需，保证公司能源供应的稳定性，同时减少公司未 来的关联交易，公司决定以自有资金向济南瑞新新能源有限公司、济南瑞金新能 源有限公司购买其所持有的电站资产组。该资产组主要为分布在山东力诺特种玻 璃股份有限公司厂房屋顶上部的电站设备，且电站所产生的电力全部向公司销售。 根据中联资产评估集团山东有限公司出具的《评估报告》（中联鲁评报字 【2023】第 13204 号、中联鲁评报字【2023】第 13205 号），以 2023 年 6 ...

山东力诺特种玻璃股份有限公司 独立董事关于第三届董事会第十八次会议相关事项 的独立意见 山东力诺特种玻璃股份有限公司（以下简称"公司"）于 2023 年 8 月 16 日召开了公司第三届董事会第十八次会议。根据《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《上市公司独立董事规则》等相关法律、法规、规范性文件和《公司章 程》的规定，作为公司的独立董事，本着认真、负责的态度，对公司第三届董事 会第十八次会议的相关议案进行了审议，现基于独立判断立场，发表独立意见如 下： 一、关于购买电站资产组暨关联交易的独立意见 独立董事：蒋灵、李奇凤、邢乐成 年 月 日 经审阅相关资料以及与公司保持充分沟通，我们认为本次购买济南瑞新新能 源有限公司、济南瑞金新能源有限公司电站资产组是公司基于整体业务发展的综 合考虑，符合公司战略发展目标和实际经营情况，有利于促进公司长远发展；交 易价格在第三方机构评估结果基础上确定，交易价格定价合理、公平、公允，符 合公司和全体股东的利益，不存在损害中小股东利益的情形；本次交易审议程序 符合相关法律法规和《公司章程》的规定，合法 ...

山东力诺特种玻璃股份有限公司 独立董事关于第三届董事会第十八次会议 根据《上市公司独立董事规则》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》和公 司章程有关规定，我们作为山东力诺特种玻璃股份有限公司（以下简称"公司"） 的独立董事，基于独立判断的立场，本着对公司、全体股东负责的态度，对公司 拟提交第三届董事会第十八次会议审议的《关于购买电站资产组暨关联交易的议 案》进行了事前审核并发表事前认可意见如下： 经审阅相关资料，我们认为本次向济南瑞新新能源有限公司、济南瑞金新能 源有限公司购买电站资产组暨关联交易事项，交易价格系根据具有证券、期货相 关评估业务资格的评估机构出具的评估报告确定，交易价格公允，不存在损害公 司和股东尤其是中小股东利益的情形，不会对公司独立性产生影响。我们一致同 意将上述议案提交董事会审议。 独立董事：蒋灵、李奇凤、邢乐成 年 月 日 相关事项的事前认可意见 ...

证券代码：301188 证券简称：力诺特玻 山东力诺特种玻璃股份有限公司 投资者关系活动记录表 编号：2023-004 特定对象调研 ☐分析师会议 ☐媒体采访 ☐业绩说明会 投资者关系活动类别 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 形式 现场 ☐网上 ☐电话会议 | --- | |-----------------------------------| | 申浩；中金证券 杨茂达、俞 | | 马锐、戴天荣；中欧瑞博投资 瞿 | | 王家豪、薛赛锋；源峰资本 林娜、耿 | | 徐胜佳。 | 参与单位名称及人员 姓名 时间 2023年6月5日-2023年6月9日 地点 公司会议室 上市公司接待人员姓名 董事会秘书、副总经理：谢岩先生 证券事务代表：王月卫先生 1、请问公司，2023年一季度公司出现了增收不增利 的情况，主要是什么原因？公司有什么对策？ 答：您好，2023年公司药用玻璃业务和耐热玻璃业务 营业收入均实现了正增长，其中药用玻璃仍然保持着较快 投资者关系活动主要 的增长速度，从收入端看，药用玻璃在营收中的占比首次 超过耐热玻璃业务，公司的战略调整效果初步显现。 从利润端 ...

证券代码：301188 证券简称：力诺特玻 山东力诺特种玻璃股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|---------------------------------|----------| | | | 2023-003 | | | ☐特定对象调研 | | | | ☐媒体采访 | | | 投资者关系活动类别 | ☐新闻发布会 | | | | ☐现场参观 | | | | ☐其他（请文字说明其他活动内容） | | | 参与单位名称 | | | | | 线上参与公司2022 | | 及人员姓名 时间 2023年05月06日 15:00-16:00 地点 价值在线（https://www.ir-online.cn/）网络互动 上市公司接待人员姓名 董事长：孙庆法先生；副董事长、总经理：杨中辰先 生；董事、副总经理：李雷先生；董事、副总经理：宋 来先生；副总经理、董事会秘书：谢岩先生；财务总 监：李国先生；独立董事：李奇凤女士；保荐代表人： 杜慧敏女士。 1.请问公司目前对于特种玻璃的研发有哪些新突 破？可否简单介绍一下亮点？ 答:您好，在 ...

Financial Performance - The company's operating revenue for 2022 was ¥822,021,882.39, a decrease of 7.52% compared to ¥888,879,852.56 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥116,654,713.97, down 6.51% from ¥124,780,673.54 in the previous year[23] - The net profit after deducting non-recurring gains and losses was ¥93,934,510.14, reflecting a decline of 19.13% from ¥116,149,697.65 in 2021[23] - The basic earnings per share decreased by 28.57% to ¥0.50 from ¥0.70 in 2021[23] - The total assets at the end of 2022 amounted to ¥1,639,985,541.85, an increase of 5.08% from ¥1,560,702,198.00 at the end of 2021[23] - The net assets attributable to shareholders increased by 5.17% to ¥1,431,238,633.59 from ¥1,360,896,593.04 in 2021[23] - The cash flow from operating activities for 2022 was ¥46,385,224.43, down 11.59% from ¥52,467,645.38 in the previous year[23] - The weighted average return on equity decreased to 8.38% from 18.60% in 2021, a decline of 10.22%[23] - The company reported a quarterly revenue of ¥252,822,079.78 in Q4 2022, which was the highest among the four quarters[25] Market and Industry Trends - The pharmaceutical glass market in China is projected to grow at a compound annual growth rate (CAGR) of 9%, reaching over CNY 400 billion by 2025[36] - The domestic pharmaceutical glass market is experiencing a "golden period" of accelerated development due to national policies promoting quality and safety in pharmaceutical packaging[34] - The competitive landscape in the borosilicate pharmaceutical glass sector is intensifying, with leading companies expanding production capabilities to capture market share[37] Research and Development - The company invested 259.62 million yuan in research and development in 2022, with 129 technical R&D personnel, accounting for 11.81% of total employees[44] - The company is focusing on developing new technologies and products, including lightweight medicinal molded glass bottles and high borosilicate glass tubes, to enhance market competitiveness[74] - The company is committed to ensuring the timely launch of key projects, including the expansion of medium borosilicate pharmaceutical glass production and lightweight high borosilicate glass products[106] Production and Operations - The company produced 279,429.93 million units of pharmaceutical glass, an increase of 15.45% from 242,033.30 million units in 2021[66] - The company has established a full industrial chain advantage in the production of controlled bottles and borosilicate glass, enhancing market competitiveness[61] - The company’s production model is based on "sales-driven production," maintaining a certain level of safety stock to meet customer order demands while ensuring production flexibility[51] Environmental and Sustainability Initiatives - The company achieved a 58% reduction in water consumption, decreasing daily water usage from 899 tons to 250 tons[200] - The company installed photovoltaic systems on rooftops, generating approximately 4,000 kWh of clean energy daily, contributing to reduced carbon emissions[199] - The company was awarded the title of "2022 Provincial Green Factory" in Shandong and received an A-level environmental performance rating during heavy pollution weather alerts[198] Governance and Management - The company maintains an independent governance structure, with no interference from controlling shareholders in decision-making processes[128] - The company has established a robust internal control system, ensuring independent operations in assets, personnel, finance, and business[134] - The board of directors consists of 9 members, including 3 independent directors, and held nine meetings in compliance with legal requirements[123] Shareholder and Financial Management - The company distributed a cash dividend of RMB 2 per 10 shares, totaling RMB 46,482,000, which represents 100% of the total distributable profit[185] - The total remuneration for directors, supervisors, and senior management in 2022 amounted to 625.25 million yuan[169] - The company has implemented a stock incentive plan approved by the board, aimed at aligning employee interests with company performance[187] Future Outlook and Strategic Plans - The company expects a revenue growth of 10% for the next fiscal year, projecting a target revenue of 1.32 billion RMB[155] - The company plans to enhance its supply chain efficiency, aiming to reduce costs by 8% over the next year[155] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential acquisitions[155]

Financial Performance - The company's revenue for Q1 2023 was ¥224,358,717.13, representing an increase of 18.99% compared to ¥188,550,996.54 in the same period last year[5]. - Net profit attributable to shareholders decreased by 26.78% to ¥22,922,691.84 from ¥31,307,449.92 year-on-year[5]. - The total operating revenue for Q1 2023 was CNY 224,358,717.13, an increase of 19.05% compared to CNY 188,550,996.54 in Q1 2022[23]. - The net profit for Q1 2023 was CNY 22,922,691.84, a decrease of 26.73% from CNY 31,307,449.92 in Q1 2022[24]. - The total comprehensive income attributable to the parent company was ¥22,922,691.84, down from ¥31,307,449.92 in the previous year, reflecting a decrease of 26.5%[25]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.10, down from ¥0.13 in Q1 2022, reflecting a 23.1% decline[25]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥215,003.89, a 101.02% increase from a negative cash flow of ¥21,106,625.27 in the previous year[12]. - Cash inflow from operating activities totaled ¥175,940,732.86, slightly up from ¥174,840,478.54 in the previous year, indicating a 0.6% increase[28]. - Cash and cash equivalents at the end of Q1 2023 were ¥296,484,279.27, down from ¥322,059,409.47 at the end of Q1 2022, representing a decrease of 7.9%[29]. - The company reported cash inflow from investment activities of ¥299,563,619.46, compared to ¥219,521,896.84 in the previous year, marking a 36.4% increase[28]. - The net cash outflow from investment activities was ¥75,636,255.32, an improvement from a net outflow of ¥341,559,691.09 in the same period last year[28]. - The company experienced a net cash inflow from financing activities of ¥66,652.98, a recovery from a net outflow of ¥17,892,622.21 in Q1 2022[28]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,616,641,974.80, down 1.42% from ¥1,639,985,541.85 at the end of the previous year[5]. - The total liabilities decreased to CNY 162,482,470.19 from CNY 208,746,908.26, a reduction of 22.19%[22]. - The total equity attributable to shareholders increased to CNY 1,454,159,504.61 from CNY 1,431,238,633.59, reflecting a growth of 1.60%[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11.249 million[14]. - Linuo Investment Holding Group holds 31.12% of the shares, amounting to 72,335,407 shares, with 57,000,000 shares pledged[14]. - Jinan Hongdao New Energy Partnership holds 6.53% of the shares, totaling 15,177,000 shares[14]. - The top ten shareholders hold a significant portion of shares, with the largest shareholder holding over 31%[15]. - The company has not disclosed any financing or margin trading activities among the top ten shareholders[16]. - The total number of restricted shares at the end of the period is 81,648,593 shares, with no shares released during the period[17]. - The company plans to grant 120,000 restricted stocks to two incentive objects as part of its incentive plan[18]. Operational Developments - The company successfully ignited the furnace for the lightweight high borosilicate glassware production project on March 9, 2023, which is expected to enhance product competitiveness and positively impact future operating performance[18]. - The first furnace for producing high borosilicate LED optical lens glass was ignited on March 21, 2023, utilizing imported German equipment[18]. - The company aims to further diversify its product categories in the high borosilicate glass sector, which is expected to enhance its market position[18]. Expenses - Sales expenses increased by 25.73% to ¥7,447,104.81, primarily due to higher market development costs and increased personnel expenses[10]. - The company's R&D expenses for Q1 2023 were CNY 6,926,478.49, an increase of 15.49% from CNY 5,996,354.46 in Q1 2022[24]. - The company reported a decrease in income tax expenses by 43.69%, amounting to ¥2,702,512.02 compared to ¥4,799,208.65 in the same period last year[10].